Table 3 Correlation between Braf/p300 staining and tumor size, and ulceration status in 327 melanoma patients
From: A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma
| Â | Tumor size | Â | |
|---|---|---|---|
|  | ≤ 2 mm | > 2 mm | p-value* |
Braf | Â | Â | Â |
Low | 38 (41.8%) | 25 (24.5%) | 0.011 |
High | 53 (58.2%) | 77 (75.5%) | Â |
Nuclear p300 | Â | Â | Â |
Low | 33 (36.3%) | 43 (42.2%) | 0.403 |
High | 58 (63.7%) | 59 (57.8%) | Â |
Cytoplasmic p300 | Â | Â | Â |
Low | 55 (60.4%) | 46 (45.1%) | 0.033 |
High | 36 (39.6%) | 56 (54.9%) | Â |
Braf and nuclear p300 | Â | Â | Â |
Low Braf and low p300 | 11 (12.1%) | 13 (12.7%) | 0.035 |
Low Braf and high p300 | 27 (29.7%) | 13 (12.7%) | Â |
High Braf and low p300 | 22 (24.2%) | 30 (29.4%) | Â |
High Braf and high p300 | 31 (34.1%) | 46 (45.1%) | Â |
Braf and cytoplasmic p300 | Â | Â | Â |
Low Braf and low p300 | 22 (24.2%) | 18 (17.6%) | 0.001 |
Low Braf and high p300 | 16 (17.6%) | 7 (6.9%) | Â |
High Braf and low p300 | 33 (36.2%) | 28 (27.5%) | Â |
High Braf and high p300 | 20 (22.0%) | 49 (48.0%) | Â |
| Â | Ulceration status | Â | |
| Â | Absent | Present | Â |
Braf | Â | Â | Â |
Low | 53 (36.8%) | 10 (20.4%) | 0.034 |
High | 91 (63.2%) | 39 (79.6%) | Â |
Nuclear p300 | Â | Â | Â |
Low | 55 (38.2%) | 21 (42.9%) | 0.564 |
High | 89 (61.8%) | 28 (57.1%) | Â |
Cytoplasmic p300 | Â | Â | Â |
Low | 79 (54.9%) | 22 (44.9%) | 0.223 |
High | 65 (45.1%) | 27 (55.1%) | Â |
Braf and nuclear p300 | Â | Â | Â |
Low Braf and low p300 | 18 (12.5%) | 6 (12.2%) | 0.199 |
Low Braf and high p300 | 35 (24.3%) | 5 (10.2%) | Â |
High Braf and low p300 | 37 (25.7%) | 15 (30.6%) | Â |
High Braf and high p300 | 54 (37.5%) | 23 (46.9%) | Â |
Braf and cytoplasmic p300 | Â | Â | Â |
Low Braf and low p300 | 32 (20.8%) | 8 (16.3%) | 0.119 |
Low Braf and high p300 | 21 (13.6%) | 2 (4.1%) | Â |
High Braf and low p300 | 47 (30.5%) | 14 (28.6%) | Â |
High Braf and high p300 | 54 (35.1%) | 25 (51.1%) | Â |